Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 65

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 65
---
, including, among other things, a merger, sale of substantially all of our assets, tender offer,
exchange offer and other business combination transactions, then upon any subsequent exercise of a warrant, the holder thereof shall have
the right to receive, for each Ordinary Share represented by the Depositary Shares that would have been issuable upon such exercise immediately
prior to the occurrence of such fundamental transaction, the number of shares of the successor’s or acquiring corporation’s
securities, if it is the surviving corporation, and any additional consideration receivable as a result of such fundamental transaction
by a holder of the number of Ordinary Shares represented by the Depositary Shares for which the warrant is exercisable immediately prior
to such fundamental transaction.

Transferability.Each
warrant and all rights thereunder are transferable, in whole or in part, upon surrender of the warrant, together with a written assignment
of the warrant subject to applicable securities laws. We do not intend to apply for listing of the warrants on any securities exchange
or other trading system.

No Rights as Shareholder Until Exercise.Except as set forth in the warrants, the holders of the warrants do not have any voting rights, dividends or other
rights as a holder of our capital stock until they exercise the warrants.

| 40 |

May 2020 United Kingdom Placing Warrants

On May 22, 2020, we issued
333,333 units, with each unit comprising one new Ordinary Share and one warrant to purchase one new Ordinary Share, or a UK Warrant. The
exercise price of the UK Warrants are £6.80 per share and they expire on November 20, 2025. We also issued UK Warrants to purchase
a total of 16,400 Ordinary Shares to Turner Pope, the placing agent, in connection with the closing of such offering, on the same terms
and conditions as the other investors in the offering.

February Placement Agent Warrants

The following is a brief summary
of the February Placement Agent Warrants, and is subject in all respects to the provisions contained in the warrant, which is filed as
an exhibit to our Report on Form 6-K dated February 9, 2023.

Exercisability.The
February Placement Agent Warrants are exercisable and expire three years from the initial exercise date. The holder shall deliver the
aggregate exercise price for the Depositary Shares specified in the exercise notice within two trading days following the date of exercise
(subject to the ‘cashless exercise’ arrangements described